Truncated c-Myb expression in the human leukemia cell line TK-6

Area of Science:

• Molecular Biology
• Oncology
• Hematopoiesis

Background:

• The c-MYB proto-oncogene is crucial for hematopoiesis.
• Leukemia cell lines can harbor genetic alterations affecting c-MYB.
• Understanding c-MYB mutations aids in comprehending leukemia pathogenesis.

Purpose of the Study:

• To characterize a truncated c-MYB mRNA and protein in the TK-6 leukemia cell line.
• To investigate the functional significance of the identified c-MYB mutation.
• To determine if the mutation was acquired during disease progression.

Main Methods:

• cDNA library screening and sequencing to isolate and analyze mutated c-MYB (WTK-1).
• Luciferase reporter assays to assess the transcriptional activity of the mutated Myb protein.
• Southern blot and PCR to analyze the c-MYB gene rearrangement in patient specimens.

Main Results:

• A truncated c-MYB mRNA (2.0 kb) and a 55 kDa Myb protein were detected in TK-6 cells.
• The WTK-1 clone revealed a mutation at the 3' end of exon 9, leading to a truncated protein (Myb(TK-6)) lacking the negative regulatory domain.
• Myb(TK-6) demonstrated enhanced transcriptional activity compared to wild-type c-Myb, suggesting transforming potential.
• The c-MYB gene rearrangement was present in late-stage but not early-stage patient samples.

Conclusions:

• The TK-6 cell line expresses a constitutively active, truncated c-Myb protein (Myb(TK-6)).
• This mutation likely contributes to leukemogenesis and was acquired during the progression of chronic myelogenous leukemia.
• The findings highlight the role of acquired c-MYB mutations in myeloid malignancies.